Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Biologic Trials

Maryland

Colorectal cancer biologic therapy trials in Maryland

11 colorectal cancer biologic therapy studies are recruiting participants at sites in 3 cities across Maryland as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 413-6546
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Maryland by city

Cities with the most studies recruiting right now.

Every Maryland city with a recruiting study

Bethesda (6), Baltimore (5), Frederick (2).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Maryland

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

    • Phase 2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT01174121 · updated
  2. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Baltimore
    Registry record
    NCT06997497 · updated
  3. Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

    • Phase 1/2
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT06149481 · updated
  4. Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

    • Phase 1
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT06885697 · updated
  5. Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

    • Phase 1/2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT03190941 · updated
  6. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Baltimore · Frederick
    Registry record
    NCT06662786 · updated
  7. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Baltimore · Frederick
    Registry record
    NCT06750094 · updated
  8. E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Christian Hinrichs
    Recruiting in
    Bethesda
    Registry record
    NCT05686226 · updated
  9. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Recruiting in
    Baltimore
    Registry record
    NCT07222800 · updated
  10. Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Baltimore
    Registry record
    NCT07147231 · updated
  11. Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Recruiting in
    Bethesda
    Registry record
    NCT05855200 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Maryland on ClinicalTrials.gov.

Ask about studies in Maryland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Colorectal Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 413-6546

or send a short form

How should we reach you?

Call